CPR Prescription Program
In this study we hope to show that prescriptions provided for CPR Anytime™ to patients who are at risk for or have heart disease at three key locations, can motivate families to learn the skill. We will use our ED sites, an office based primary care setting, and an office based cardiology practice. Participants will be given the pharmacy locations where they can be purchased. Optimally they will complete the program at home with their family.
Research Hypothesis:
- Families of patients at risk for coronary artery disease can be motivated to learn CPR by receiving a prescription for a CPR Anytime ™ self learning kit.
- As part of the multiplier effect, an additional 1.5 family members per participant are projected to be trained to perform CPR.
- Families may experience a "teachable moment" when their loved one is in the emergency department. In comparison to the office settings, this may increase the likelihood that they fill the prescription for CPR Anytime® and complete the learning kit.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This will be a prospective study of patients presenting to one of three recruiting sites (emergency department and office based primary care/cardiology settings). Physicians at all settings will agree to be a part of the Physician CPR Prescription program. Participating physicians are provided with a description of the Physician CPR Prescription program and pre-printed CPR prescription pads. The front side of the prescription is preprinted with the information needed to obtain CPR Anytime ™ for Friends and Family. The back of the prescription is preprinted with "Quick Facts" to assist the physician in delivering a consistent and persuasive CPR message to patients and their families.
After consent, participants will be randomized to one of two groups. The control group will be advised to take a traditional CPR class and be offered a list of local classes. Phone follow up at approximately 3 months will assess their participation. The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program. Follow up phone survey at approximately three months will assess compliance with physician recommendations to fill the prescription, as well as actual completion of the materials (and possible multiplier effect).
Comparisons between the sites regarding efficacy of prescribing will be performed. Results will be reported as mean +/- standard deviation, % or frequencies to summarize patient characteristics. One way ANOVA will be used to compare the three groups for continuous data and chi-square for categorical data.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English speaking
- 45 or older
- Competent outpatient.
- Have DVD access in home.
- Willing to fill prescriptions at Spectrum pharmacy.
- Never had CPR, or CPR greater than 1 year ago.
- Have a risk factor for heart disease or have heart disease.
Exclusion Criteria:
- Non English speaking
- Minors
- Incompetent or significantly ill/distressed
- No DVD access
- Unwilling to fill rx at spectrum.
- CPR less than 1 year ago.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Class
The control group will be advised to take a traditional CPR class and be offered a list of local classes.
|
The study group will be asked to fill the CPR Anytime ™ prescription and complete the program.
They will be encouraged to include other friends and family members in the program
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Completion of CPR
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Family Member completion of CPR
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marna R Greenberg, D.O., LVH
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2-20070910
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Sudden Death
-
NCT00570869CompletedPrevention of Sudden Death
-
NCT01736618CompletedPrimary Prevention of Sudden Cardiac Arrest | Secondary Prevention of Sudden Cardiac Arrest
-
NCT01596595CompletedPrimary Prevention of Sudden Cardiac Arrest | Secondary Prevention of Sudden Cardiac Arrest
-
NCT00947310CompletedPrimary Prevention of Sudden Cardiac Arrest
-
NCT05373940RecruitingHeart Failure | Implantable Cardioverter Defibrillator | Primary Prevention of Sudden Cardiac Death
-
NCT01378572UnknownDilated Cardiomyopathy | Implantable Cardioverter Defibrillator | Primary Prevention of Sudden Cardiac Death
-
NCT03590730TerminatedPrimary Prevention | Valvular Heart Disease | Sudden Cardiac Death | Implantable Cardioverter Defibrillator
-
NCT00619593CompletedTachycardia, Ventricular | Primary Prevention | Sudden Cardiac Death
-
NCT01058837UnknownCongestive Heart Failure | Left Ventricular Systolic Dysfunction | Ischemic and Non-ischemic Cardiomyopathy | Sudden Cardiac Death Primary Prevention
-
NCT02056509UnknownOut-of-Hospital Cardiac Arrest | Sudden Cardiac Death
Clinical Trials on CPR Anytime Kit
-
NCT01833910CompletedHeart Disease | Cardiac Arrest
-
NCT01260441CompletedCoronary Disease | Cardiac Arrest | Cardiovascular Risk Factors
-
NCT02548793CompletedCoronary Disease | Cardiac Arrest | Cardiovascular Risk Factors
-
NCT00570869CompletedPrevention of Sudden Death
-
NCT01252316CompletedCoronary Disease | Cardiac Arrest | Cardiovascular Risk Factors
-
NCT00570609CompletedCoronary Atherosclerosis | Prevention of Heart Disease
-
NCT01514656CompletedCoronary Disease | Cardiac Arrest | Cardiovascular Risk Factors
-
NCT02401633CompletedCardiac Arrest | Out of Hospital Cardiac Arrest
-
NCT07546474CompletedEmergency Medical Services | Out-of-hospital Cardiac Arrest (OHCA)